Stock LIFE ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-07 EDT 		5-day change 1st Jan Change
1.7 USD +2.41% Intraday chart for aTyr Pharma, Inc. +8.28% +20.57%
05-02 ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-02 Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ATyr Pharma to Present at Upcoming Investor Conferences
AQ
Atyr Pharma: Q1 Earnings Snapshot
AQ
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
AQ
ATyr Pharma to Participate in April Investor Conferences
AQ
Atyr Pharma: Q4 Earnings Snapshot
AQ
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
AQ
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
AQ
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
AQ
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
AQ
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
AQ
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
AQ
Atyr Pharma: Q3 Earnings Snapshot
AQ
ATyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
AQ
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD
AQ
ATyr Pharma to Present at November Investor Conferences
AQ
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
AQ
ATyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
AQ
ATyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
AQ
Atyr Pharma: Q2 Earnings Snapshot
AQ
ATyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIFE Stock
  4. News aTyr Pharma, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW